Información del producto
GSK4112 is a novel, orally bioavailable compound that is being developed for the treatment of metabolic disorders and bowel diseases. GSK4112 inhibits the production of tumor necrosis factor-α (TNF-α) and other pro-inflammatory cytokines in vitro, as well as downregulates toll-like receptor 4 (TLR4) expression in vivo. GSK4112 has been shown to protect 3T3-L1 preadipocytes from induced apoptosis and reduce the size of fat cells without affecting their viability. These effects are due to increased autophagy and decreased lipid accumulation. The oral bioavailability of GSK4112 was found to be high in vivo.
Propiedades químicas
Consulta técnica sobre: 3D-RYB74419 GSK4112
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
